Impact of excipient differences on the clinical performance of generic oral formulations: A narrative review and descriptive comparison

Abstract

Generic substitution is widely promoted to contain healthcare costs, yet variability in excipient composition across formulations has raised clinical concerns. This study aimed to highlight how excipient differences may relate to clinical observations during formulation switches. We conducted a narrative review with a descriptive comparison of excipient listings from publicly available package inserts for five commonly prescribed oral drugs in Japan (pravastatin, valproic acid, fosfomycin, amlodipine, and clarithromycin). Anecdotal clinical observations from daily practice were included as hypothesis-generating context. All five drugs exhibited variability in excipient profiles. In pravastatin, generics differed in binders and fillers; an anecdotal case of CPK elevation after a switch illustrates a hypothesis-generating signal, although causality cannot be established. For valproic acid, reports suggested seizure recurrence after formulation changes, consistent with cautions regarding its narrow therapeutic index. In fosfomycin calcium, a pediatric case showed a drug-induced lymphocyte stimulation test (DLST) positive only for the generic capsule; PEG 6000 and other excipients may have contributed as a hypothesis-generating association. For amlodipine, generics are generally regarded as equivalent, but isolated cases described flushing after generic-to-generic switches, possibly linked to excipient differences. In pediatric clarithromycin formulations, differences in sweeteners and flavoring agents may have influenced palatability and caregiver perceptions. Excipient variability may, in rare cases, modulate tolerability, adherence, or perceived effectiveness. These findings are hypothesis-generating and highlight the need for transparent excipient disclosure, careful monitoring during product switches, and further mechanistic and pharmacoepidemiological research.